Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod
 versus interferon β-1a to reduce the frequency of relapses in patients with
 relapsing-remitting multiple sclerosis.
Inclusion Criteria:

 -  Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis
 (MS)

 -  Patients with a relapsing-remitting disease course

 -  Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5

 Exclusion Criteria:

 -  Patients with other chronic disease of the immune system, malignancies, acute
 pulmonary disease, cardiac failure, etc

 -  Pregnant or nursing women

 -  Patients who cannot tolerate treatment with an interferon

 Other protocol-defined inclusion/exclusion criteria applied to the study.